Abstract Number: 2417 • 2014 ACR/ARHP Annual Meeting
Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Background/Purpose: : to stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis.…Abstract Number: 1383 • 2014 ACR/ARHP Annual Meeting
Disease Characteristics and RA Development in Undifferentiated Arthritis: A 2-Year Follow-up Study of 413 Patients with Arthritis of Less Than 16 Weeks Duration
Background/Purpose: Correct identification of the subset of patients with undifferentiated arthritis (UA) who will develop rheumatoid arthritis (RA) is important to enable initiation of appropriate…Abstract Number: 374 • 2014 ACR/ARHP Annual Meeting
IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Background/Purpose Clinical remission is achievable for patients with early rheumatoid arthritis (ERA). Identification of predictors for response of treatment may provide risk estimation and help…Abstract Number: 2689 • 2013 ACR/ARHP Annual Meeting
Assessing Maintenance Of Remission After Withdrawal Of Etanercept Plus Methotrexate, Methotrexate Alone, Or Placebo In Early Rheumatoid Arthritis Patients Who Achieved Remission With Etanercept and Methotrexate: The Prize Study
Background/Purpose: In the PRIZE study patients (pts) with early (mean 6 mos. since symptom onset) moderate-severe rheumatoid arthritis (RA), who achieved remission after open-label treatment…Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting
Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…Abstract Number: 2646 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial
Background/Purpose: The long-term cost-effectiveness of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ]) disease modifying anti-rheumatic drugs (DMARDs) compared to a combination of MTX and…Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…Abstract Number: 449 • 2013 ACR/ARHP Annual Meeting
Work Instability In Early Rheumatoid Arthritis With Elevated Risk Of Employment Loss: Effects Of Adalimumab/Methotrexate Combination Therapy Versus Methotrexate In a Randomized Clinical Trial
Background/Purpose: Intensive treatment of early rheumatoid arthritis (RA) has been shown to reduce functional disability over time and to positively impact employment outcomes. Adalimumab (ADA)…Abstract Number: 2359 • 2013 ACR/ARHP Annual Meeting
Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial)
Background/Purpose: Active rheumatoid arthritis (RA) is commonly associated with impairment of physical function and health-related quality of life (QoL), as well as work disability. The…Abstract Number: 1358 • 2013 ACR/ARHP Annual Meeting
No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Background/Purpose: Methotrexate (MTX) in combination with the tumor necrosis factor inhibitor adalimumab (ADA) is an effective therapy for treating rheumatoid arthritis (RA), but the minimum…Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…Abstract Number: 2294 • 2013 ACR/ARHP Annual Meeting
The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis From The Norwegian Very Early Arthritis Clinic
Background/Purpose: In the ACR/EULAR criteria remission can be defined in two ways, either by fulfilment of 4 Boolean criteria or by a Simplified Disease Activity…Abstract Number: 1361 • 2013 ACR/ARHP Annual Meeting
Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort
Background/Purpose: Prognosis of the patients with rheumatoid arthritis (RA) nowadays is supposed to become better by treat-to-target (T2T) strategy. Osteitis determined by magnetic resonance imaging…Abstract Number: 416 • 2013 ACR/ARHP Annual Meeting
Changes In Body Composition On Two Different Glucocorticoid Regimens In Early RA: Experience From The Cobra-Light Trial
Background/Purpose: Prednisolone improves joint inflammation and disease severity in rheumatoid arthritis (RA), but is associated with multiple cardiovascular, metabolic and endocrine side effects and may…
ACR Meeting Abstracts